CODE chemotherapy with and without granulocyte colony-stimulating factor in small-cell lung cancer

Authors:
  • NMN Masuda
    N Masuda
  • SNS Negoro
    S Negoro
  • KMK Matsui
    K Matsui
  • TYT Yana
    T Yana
  • SKS Kudoh
    S Kudoh
  • YKY Kusunoki
    Y Kusunoki
  • MTM Takada
    M Takada
  • MKM Kawahara
    M Kawahara
  • MOM Ogawara
    M Ogawara
  • NKN Kodama
    N Kodama
  • KKK Kubota
    K Kubota

Abstract
Sixty-three patients with extensive-stage small-cell lung cancer were randomized to receive either cyclophosphamide, vincristine, doxorubicin and etoposide (CODE) alone or CODE plus recombinant human granulocyte colony-stimulating factor (rhG-CSF). rhG-CSF administration in support of CODE chemotherapy resulted in increased mean total received dose intensity for all drugs (P = 0.03) with a significant improvement in survival (P = 0.004).

This publication has 17 references indexed in Scilit: